Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 11/20 | 0.39 |
| ▸ | PGR | P06401 | 5/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533328 | 0.93 | NR3C1 (0.38) | NR3C1NR3C2PGRCTSS | |
| SCHEMBL3534687 | 0.87 | NR3C1 (0.39) | NR3C1NR3C2PGRCTSS | |
| SCHEMBL3529041 | 0.86 | NR3C1 (0.42) | NR3C1NR3C2PGRCTSS | |
| SCHEMBL3532969 | 0.84 | CTSS (0.35) | NR3C1NR3C2CTSS | |
| SCHEMBL27650711 | 0.82 | NR3C1 (0.44) | NR3C1NR3C2PGR | |
| SCHEMBL5776235 | 0.82 | NR3C1 (0.42) | NR3C1NR3C2PGR | |
| SCHEMBL3533138 | 0.81 | NR3C1 (0.35) | NR3C1NR3C2PGRCTSS | |
| SCHEMBL332294 | 0.81 | NR3C1 (0.36) | NR3C1NR3C2PGR | |
| SCHEMBL3532068 | 0.80 | NR3C2 (0.49) | NR3C1NR3C2PGR | |
| SCHEMBL3532509 | 0.80 | NR3C1 (0.46) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662821-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AG (DE) | 2010-02-16 | — | — | US | disclosed |
| US-7659297-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | Bayer Schering Pharma, AG (DE) | 2010-02-09 | — | — | US | disclosed |
| CN-100581543-C | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG | 2010-01-20 | — | — | CN | disclosed |
| US-7638515-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-29 | — | — | US | disclosed |
| US-20080227820-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2008-09-18 | — | — | US | disclosed |
| WO-2008052808-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1917963-A1 | Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-07 | — | — | EP | disclosed |
| CN-1889947-A | Tetrahydronaphthalene derivatives, process for their preparation and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-01-03 | — | — | CN | disclosed |
| EP-1670458-B1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| EP-1670458-A1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-21 | — | — | EP | disclosed |
| EP-1638945-A1 | HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2006-03-29 | — | — | EP | disclosed |
| US-20050272823-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-08 | — | — | US | disclosed |
| US-20050209324-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20050171109-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-04 | — | — | US | disclosed |
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2005-04-28 | — | — | US | disclosed |
| WO-2005034939-A1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005003098-A1 | HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | IL1B, NFKBIA, BBOX1 | NR3C1 1483/4885NR3C2 872/4885PGR 3289/4885 |
| US-20080227820-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | PTGIS, PTGS1, PTGES | NR3C1 865/4885NR3C2 800/4885PGR 897/4885 |
| US-20050171109-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | TNF, DHPS, PTGES | NR3C1 1387/4885NR3C2 755/4885PGR 3963/4885 |
| US-20050272823-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | DHPS, TNF, PTGES | NR3C1 1000/4885NR3C2 511/4885PGR 3505/4885 |
| US-20050209324-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | TNF, DHPS, PTGES | NR3C1 1387/4885NR3C2 755/4885PGR 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.